Dr. Rena Buckstein is a clinician investigator at Sunnybrook Health Sciences who specializes in malignant hematology.  She is professor in the department of medicine at University of Toronto.  

She chaired the hematology site group for 15 years and currently leads the hematologyclinical trials program at the Odette Cancer Center. Rena founded and chairs a national registry for myelodysplastic syndromes (MDS-CAN) of more than 1400 patients and is an affiliate scientist of Sunnybrook Research Institute. She is a member of the International MDS Foundation scientific advisory board, i4MDS, International Working group for MDS, the Canadian Cancer Society hematology clinical trials sub-committee, a co-chair of an international MDS Guidelines panel for MDS-RIGHT and has chaired national clinical trials in lymphoma and MDS.  She has authored and co-authored 170 publications and holds peer reviewed grants from Canadian Cancer Society Research Institute (CCSRI), Canadian Institute of Health Research (CIHR), Ontario Institute for Cancer Research (OICR) and the Leukemia Lymphoma Society of Canada (LLSC).

Her interventional research focuses on novel targeted biologic and immunologic therapies for hematologic malignancies focusing on myelodysplastic syndromes and acute myelogenous leukemia and improving the transfusion experience for MDS patients.  Her non-interventional current research focuses on the impact of CHIP on chemotherapy outcomes in lymphoma patients, predictors of CVD in MDS patients, using wearables for the biometric correlates with self-rated health and longitudinal patient reported outcomes and factors in MDS patients. She collaborates on health services research pertaining to ‘real-life’ outcomes for approved therapies.

Dr. Gwynivere Davies practices malignant hematology at the Juravinski Hospital and Cancer Centre in Hamilton, Ontario, with a clinical focus on lymphoma and CLL, autologous stem cell transplantation and CAR-T. She is an Associate Professor of Oncology at McMaster University and serves as Division Head of Malignant Hematology and Director of the Lymphoma Fellowship program. Her research centers on the introduction of novel agents in frontline and relapsed/refractory lymphoma, the impact of social determinants of health on lymphoma outcomes, and health services research. Her peer-reviewed grant topics include ICES database research in indolent non-Hodgkin lymphoma and CAR-T knowledge translation, and she has led and co-authored numerous peer-reviewed studies on secondary malignancies and survival outcomes following lymphoma diagnosis and treatments, bispecific antibodies, CAR-T outcomes and toxicities and hematology residency education innovations, maintaining an active publication and presentation record at national and international conferences.

Dr. Dawn Maze is a clinician investigator at the Princess Margaret Cancer Centre and an Assistant Professor in the Department of Medicine at the University of Toronto. She is a member of the Leukemia Site Group and the Myeloproliferative Neoplasms (MPN) Program and has a clinical research interest in myeloid malignancies. Her primary research focus is in MPN, particularly in risk stratification and management approaches early in the disease course and in the adolescent/young adult population. 

She is particularly interested in optimizing pregnancy outcomes in this population. She is also actively involved in clinical trials and projects aiming to refine risk stratification in acute myeloid leukemia. Dr. Maze is an active member of the Canadian MPN Group. She is the Medical Director for the Malignant Hematology Day Unit at Princess Margaret and the Program Director for the Leukemia Fellowship Program.

Dr. Paola Neri is an Associate Professor of Medicine, attending physician in the Hematology division at University of Calgary and member of the Arnie Charbonneau Cancer Institute. Since January 2019, she has been the Scientific Director of the Cancer Translational Research Core, a clinically accredited laboratory located at the Arthur Child Comprehensive Cancer Center in Calgary.

Dr. Neri received her medical degree at Magna Græcia University, Catanzaro, Italy in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011. From 2003-2006 she was Research Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA under the mentorship of Dr. Kenneth Anderson. In June 2008, she joined the University of Calgary. The main focus of her research is the study of multiple myeloma (MM) with a particular interest in genomic studies with the goal of identifying mechanisms of drug resistance and discovering novel therapeutic targets for this incurable disease. 

Dr. Neri is well published in the field and received national and international grants from several agencies including International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation and Canadian Institute of Health Research (CIHR). In 2019 she received the Engineered Air Chair (research funds) in Cancer Research from University of Calgary. In 2021 she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her important translational work in multiple myeloma. In 2025 she has received the Global Impact in Myeloma Research Award from the Canadian Myeloma Research Group (CMRG). She is currently member of the American Society of Hematology, co-chair of Charbonneau Research & Innovation Committee in Calgary and member of Blood Editorial Board, very active both in preclinical and clinical trial research in Myeloma.

Dr. Robert Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Cancer Centre and the University of Calgary in Calgary, Canada. His main interests are in lymphoma, stem cell transplantation and cellular therapies, bispecific antibodies, clinical trials, and real-world data.

Dr. Andre Schuh is a Staff Hematologist at the Princess Margaret Cancer Centre, and a Professor of Medicine at the University of Toronto, Toronto, Ontario, Canada.

He has been at Princess Margaret since 1992, where he has focused on acute leukemia and MDS, and has managed an extensive clinical trial portfolio. In addition to a variety of other administrative roles, he was the head of the leukemia program at Princess Margaret from 2010-2014, and from 2012-2018, was Medical Director, Malignant Hematology.

His current interests include Acute Leukemia management and clinical trials (especially in the older patient), and the development of Canadian province- and country-wide leukemia management strategies. He is the founding Chair of the Canadian Leukemia Study Group (CLSG)/Groupe Canadien d’Étude Sur La Leucémie (GCEL), a country-wide cooperative of leukemia-treaters who share the goal of improving acute leukemia diagnosis and management across Canada, by identifying and defining diagnostic and management best practices, promote Canada-wide standards-of-care, fostering clinical and basic leukemia research, and improving new drug access.